Skip to main content
Full access
Articles
Published Online: 1 September 2017

Impact of Physician Follow-Up Care on Psychiatric Readmission Rates in a Population-Based Sample of Patients With Schizophrenia

Abstract

Objective:

The study evaluated the association between physician follow-up within 30 days after hospital discharge and psychiatric readmission within the subsequent 180 days.

Methods:

Among inpatients with schizophrenia who were discharged between 2007 and 2012 in Ontario (N=19,132), those who had a 30-day follow-up visit with a primary care physician (PCP) only, a psychiatrist only, or both were compared with a no-follow-up group. The primary outcome was psychiatric readmission in the subsequent 180 days. Secondary analyses stratified the sample on the basis of readmission risk at discharge.

Results:

About 65% of patients had follow-up care within 30 days postdischarge. Psychiatric readmission rates were similar among patients with any physician follow-up and significantly lower than among those with no follow-up (26%): PCP only: 22%; adjusted hazard ratio [aHR]=.88, 95% confidence interval [CI]=.81–.96; psychiatrist only, 22%; aHR=.84, CI=.77–.90; both, 21%, aHR=.82, CI=.75–.90). In stratified analyses, 66% of patients were in the category at highest risk of psychiatric readmission, and the effect of follow-up with any physician was significant for these patients, compared with high–readmission risk patients with no follow-up, who had a 29% readmission rate (PCP only, 20% readmission rate, aHR=.85, CI=.77–.94; psychiatrist only, 29%, aHR=.84, CI=.77–.92; both, 17%, aHR=.81, CI=.73–.90).

Discussion:

Timely physician follow-up was associated with reduced risk of psychiatric readmissions, with the greatest reduction among patients at high risk of readmission. Because more than one-third of patients had no physician visit within 30 days postdischarge, improving physician follow-up may help reduce psychiatric readmission rates.
Individuals with schizophrenia have high rates of psychiatric hospitalization (1) and rehospitalization. In the United States, 25% of individuals with schizophrenia are rehospitalized three months after discharge (2). The high readmission rate is likely attributable to discharge before adequate stabilization or to receipt of inadequate community-based services, neither of which reflect good care. Assertive community treatment (3) and intensive case management (4), two modes of intensive service delivery for individuals with severe mental illness, have been shown to be associated with reduced hospitalization but may not be available to, or necessary for, all patients with schizophrenia.
Although psychiatric readmission rates are high, and high quality and intensity of care appear to reduce hospitalization, only a few studies have specifically evaluated interventions to reduce readmissions. Also, these studies have focused on specific clinical populations (5) or specific postdischarge clinical interventions (6). The type of physician follow-up that reduces early psychiatric readmission is unknown. Access to psychiatrists is limited in many jurisdictions (79); individuals with schizophrenia often have access only to a primary care physician (PCP). Furthermore, individuals with schizophrenia have high rates of general medical comorbidity (10,11); access to both a PCP and psychiatrist may be necessary for optimal outcomes (12). With an increasing emphasis on collaboration between psychiatrists and PCPs in the care of patients with complex conditions, such as those with schizophrenia (1315), knowing what type of physician follow-up (for example, PCP, psychiatrist, or both) has the greatest impact is important.
The objective of this study was to evaluate the impact on readmission within the subsequent 180 days of follow-up care by a physician in the 30 days after discharge from a psychiatric inpatient unit. We hypothesized that seeing any physician after discharge would be associated with a reduction in the rate of psychiatric readmission and that patients who see a psychiatrist would have a lower risk of psychiatric readmission than patients who see a PCP only.

Methods

Data Sources

Ontario, Canada’s largest province, provides universal health coverage for all medically necessary health care. Patient-level records from multiple health administrative databases containing information on all publicly insured hospital and physician services were linked by using unique, encoded identifiers. These included the Ontario Mental Health Reporting System (OMHRS), which provides information from psychiatric hospitalizations; the Ontario Health Insurance Plan database, which provides information from physician visits; the National Ambulatory Care Reporting System for data on emergency department (ED) visits; and the Registered Persons Database for patient demographic information and deaths. Physician type (PCP or psychiatrist) was acquired from the Institute for Clinical Evaluative Sciences Physician Database. Neighborhood income level for each individual was based on his or her residential postal code and derived from Statistics Canada 2006 census estimates for income. This study was approved by the Sunnybrook Health Sciences Research Ethics Board.

Study Population

We included all adults ages 19 and older discharged with a most responsible diagnosis of schizophrenia (DSM-IV codes 295.x) between April 1, 2007, and March 31, 2012, after a nonforensic psychiatric hospitalization in Ontario that lasted three to 90 days. The most responsible diagnosis refers to the diagnosis that was the reason for the psychiatric hospitalization, as opposed to secondary diagnoses. We excluded individuals whose hospital length of stay was longer than 90 days because this relatively small number of patients with complex conditions may face specific challenges related to discharge. We also excluded individuals whose hospital length of stay was less than 72 hours because diagnostic information was missing. Similarly, we excluded a small number of individuals who were ineligible for health coverage in Ontario in the year prior to the incident admission (for example, recent immigrants). We also excluded those who died or were readmitted within 30 days of their discharge to allow a window of opportunity for patients to be seen by a PCP or a psychiatrist. For individuals with multiple hospitalizations over the study period, we included in our analysis the first hospitalization, with one exception: when a readmission occurred within 30 days of discharge from a hospitalization, that readmission was considered as the index admission, provided all other selection criteria were met.

Exposure Groups

Participants were classified into four groups on the basis of physician follow-up within 30 days postdischarge: no physician follow-up (reference group), follow-up by a PCP only, follow-up by a psychiatrist only, and follow-up by both a PCP and psychiatrist. Visits to other specialists were not considered.

Outcome

The primary outcome was readmission to a designated psychiatric bed in Ontario (that is, any readmission captured within the OMHRS database) between 31 and 210 days postdischarge to allow for a 30-day physician follow-up window after the discharge date and 180 days for outcome observation. The 180-day outcome period was chosen to be long enough to detect an effect but within a period when physician visits would be associated with readmission. Because a death would preclude a rehospitalization, we also assessed all-cause mortality between 31 and 210 days postdischarge. Physician follow-up in the outcome observation period (31–210 days) could influence readmission rates, and patients who did not receive follow-up within 30 days could have received follow-up shortly after the 30-day exposure period. Therefore, we measured PCP and psychiatrist visits in two periods during the outcome period—early (31 to 60 days) and late (31 to 210 days) to determine consistency of follow-up during the first 30 days throughout the outcome period. Consistent physician engagement (or lack of engagement) throughout both the exposure and outcome periods further establishes the association between physician follow-up and psychiatric readmission risk.

Covariates

Sociodemographic characteristics included age, sex, neighborhood income quintile, and residence (rural versus urban). We measured number of ED visits and psychiatric hospitalizations 12 months prior to admission. Health service utilization measures during the six months prior to the index hospitalization included visits to a psychiatrist or a PCP; PCP visits were categorized as mental health related or non–mental health related on the basis of a validated algorithm (16). General medical comorbidities in the 12 months prior to the index hospitalization were identified by using the Johns Hopkins composite Aggregated Diagnostic Groups (cADGs), which provide 12 groupings of comorbidity categories based on prior health care utilization; these categories are good predictors of mortality in the general population (17) and among persons with schizophrenia (18).
Psychiatric symptom severity and psychosocial functioning at discharge were measured on the basis of information from the Resident Assessment Instrument for Mental Health (Inter-RAI-MH) (19,20), which was administered at the time of discharge and is part of the OMHRS data set. We included variables based on the following rating scales, which are included in the Inter-RAI-MH: Aggressive Behavior Scale, Activities of Daily Living Scale, Cognitive Performance Scale, Depression Rating Scale, Positive and Negative Syndrome Scale, CAGE Questionnaire, Suicide Behaviors Scale, and Global Assessment of Functioning (21).
We used a validated readmission risk prediction tool (READMIT) (22) to stratify the sample into three readmission risk categories (low, medium, and high). The READMIT was developed by using all psychiatric hospitalizations in Ontario between 2008 and 2011; it uses information available at the time of discharge to predict the probability of readmission. The READMIT generates scores between 0 and 41; a score <15 indicates a low risk of readmission, 15–18 indicates a medium risk, and >18 indicates a high risk.

Statistical Analysis

In the primary analysis, time to psychiatric readmission or death between 31 and 210 days after discharge from the index hospitalization was analyzed by using a Cox proportional hazards (PH) model. Patients with no physician follow-up visit formed the reference group. We adjusted for the following patient characteristics: demographic (age, sex, age-sex interactions, neighborhood income, and rural versus urban residence), clinical (cADGs in the 12 months preceding admission and psychiatric symptom severity and psychosocial functioning at discharge as measured by the Inter-RAI Mental Health [19]), and health service utilization variables (total number of prior psychiatric hospitalizations and total number of prior ED visits). For the main outcome analyses (psychiatric readmissions) and the main sensitivity analyses (psychiatric readmission or death), the regression models included demographic variables, clinical variables, and health service utilization variables. Patient data were censored if the patient died during the follow-up period; we conducted a sensitivity analysis that combined death with psychiatric readmission as an outcome.
In secondary analyses, we stratified the cohort into psychiatric readmission risk tertiles. We also tested whether the timing of a physician visit (PCP or psychiatrist) postdischarge influenced readmission risk by categorizing patients into different postdischarge physician visit time periods (first visit within one to seven days, eight to 14 days, or 15 to 30 days postdischarge), with no physician visit as the reference group. Violation of the Cox PH proportionality assumption was tested by using time-dependent covariates in all analyses. We used SAS version 9.3 (23) for all statistical analyses.

Results

Cohort Description

Between April 1, 2007, and March 31, 2012, a total of 22,640 unique patients had 47,280 hospitalizations associated with a most responsible discharge diagnosis of schizophrenia. [A figure presenting details on cohort creation is included in an online supplement to this article.] Exclusion criteria were applied to both hospitalizations and patients; 2,667 hospitalizations were excluded because of a missing discharge assessment or other missing data, 4,788 because the hospital length of stay was less than three or more than 90 days, and 6,105 because the patient was readmitted within 30 days postdischarge (the readmission was potentially eligible for cohort inclusion). Patients were excluded if they were younger than 19 or older than 105 (N=614), ineligible for health insurance in the year prior to admission (N=686), or died within 30 days postdischarge (N=68). In total, there were 3,508 patients (15%) excluded for reasons cited above. The excluded patients differed from the final cohort in readmission risk at discharge and in age [see table in online supplement]. The final cohort in readmission risk at discharge and in age [see table in online supplement]. Considering only the first eligible hospitalization during the study period, the final cohort comprised 19,132 unique patients with a discharge diagnosis of schizophrenia (85% of all hospitalized schizophrenia patients), of whom 6,649 (35%) did not have any follow-up visits with a PCP or a psychiatrist within 30 days of discharge; 4,026 (21%) saw a PCP only; 5,374 (28%) saw a psychiatrist only; and 3,083 (16%) saw both a PCP and psychiatrist.

Baseline Characteristics

Psychiatric symptoms or psychosocial functioning at discharge, proportion with ED visits (all cause), psychiatric hospitalizations within 12 months preceding the index admission, and mean psychiatric readmission risk at discharge were similar across the four follow-up groups (Table 1). However, there were notable differences in sociodemographic variables and in some health service use: patients followed up by a PCP (with or without a psychiatrist) were more likely to be women and older, compared with those not followed up or followed up by a psychiatrist only. Patients followed up by a psychiatrist (with or without a PCP) were more likely to reside in urban areas, compared with those not followed up or followed up by a PCP only. The type of physicians that patients saw prior to the index admission was strongly indicative of the type of physician they saw postdischarge.
TABLE 1. Baseline characteristics of patients discharged with a diagnosis of schizophrenia, by whether they had a follow-up visit with a primary care physician (PCP) or a psychiatrista
 No physician follow-up (N=6,649)PCP only (N=4,026)Psychiatrist only (N=5,374)PCP and psychiatrist (N=3,083)
CharacteristicN%N%N%N%
READMIT score at discharge (M±SD)b20.32±4.32 20.13±4.34 20.41±3.96 20.5±4.16 
READMIT risk tertiles        
 Low (0–14)5729374933162187
 Medium (15–18)1,691251,139281,4082675325
 High (19 and over)4,386662,513623,635682,11269
Sociodemographic        
 Female2,441371,898471,969371,46748
 Age        
  19–393,164481,467373,052571,30942
  40–643,124472,178542,153401,57251
  ≥6535153811016932027
 Income in lowest quintiles (1 or 2) of neighborhood income4,052612,459612,998561,75257
 Urban residence6,12392.13,746935,198972,98497
Health care use prior to admission        
 Any PCP visit within 6 months3,599543,467863,251612,65186
  Mental health reason2,056312,358591,793331,73856
  Non–mental health reason2,693412,862712,569482,26874
 Any psychiatrist visit within 6 months2,679401,607404,025752,29574
 Any emergency department visit within 12 months4,206632,776693,465652,12969
 Any psychiatric hospitalization within 12 months1,991301,043261,6233087328
N of Johns Hopkins cADGs (M±SD)c2.62±1.75 3.58±1.80 2.85±1.63 3.82±1.76 
Index hospitalization variables        
 Length of stay (median, interquartile range)18, 10–33 18, 10–32 19, 11–33 18, 11–30 
 GAF score at discharge (M±SD)d53.53±13.21 54.41±13.16 54.97±12.63 55.54±12.47 
 Symptom severity and psychosocial functioning at discharge        
  Aggressive Behavior Scalee        
   05,256793,280824,599862,61885
   12844165421441214
   24587282725151505
   ≥365110299731061946
  Cognitive Performance Scalef        
   04,234642,550633,757702,07067
   11,51923853211,0832065321
   ≥289614623165321036012
  Depression Rating Scaleg        
   03,850582,276573,302611,71056
   191914598157581444615
   291514518136571241013
   ≥396515634166571251717
  Total N of positive symptoms        
   03,380512,190542,865551,68855
   11,36721796201,1602260420
   21,10517605158431650116
   ≥37971243511507102909
  Total N of negative symptoms        
   04,126622,683673,453642,00865
   11,09216581148171546715
   26119284743182187
   ≥382012478126731339013
  CAGE Questionnaireh        
   05,659853,522884,717882,75589
   13465164425151194
   23445179422641053
   ≥32995161418031053
  Suicidal behaviors1,506231,0222513,8612685428
  Activities of Daily Living Scalei        
   06,030913,593895,055942,86093
   1326518951833933
   ≥22934244613631304
a
All differences across groups were statistically significant (p<.001).
b
The READMIT tool generates scores from 0 to 41, with higher scores indicating greater likelihood of being readmitted within 30 days of discharge from a psychiatric hospitalization.
c
ADG, Johns Hopkins composite Aggregated Diagnostic Groups
d
Global Assessment of Functioning. Possible scores range from 0 to 100, with higher scores indicating better functioning.
e
Possible scores range from 0 to 5, with higher scores indicating higher risk for aggressive behaviour.
f
Possible scores range from 0 to 6, with higher scores indicating worse cognitive performance.
g
Possible scores range from 0 to 14, with higher scores indicating worse depression.
h
Possible scores range from 0 to 4, with higher scores indicating more problematic alcohol use.
i
Possible scores range from 0 to 6, with higher scores indicating greater impairment with activities of daily living.

Outcomes

The psychiatric readmission rate in the entire cohort was 23% (N=4,421 of 19,132 patients). Patients with no physician visit within 30 days postdischarge had the highest rate of psychiatric readmission (26%) within 31–210 days (Table 2). Rates of psychiatric readmission were modestly but significantly lower among those who were followed up by any of the three physician follow-up categories, compared with those with no physician visit. Results were unchanged when death was combined with psychiatric readmission in the outcome (Table 2). For both outcomes, the adjusted hazard ratios (aHRs) for physician follow-up did not vary with sequential inclusion of demographic, clinical, and health service utilization covariates.
TABLE 2. Readmission rates between 31 and 210 days postdischarge for patients with schizophrenia, by whether they had a follow-up visit with a primary care physician (PCP) or a psychiatrist and by timing of visit
 Proportional hazard modelsa
 ReadmittedDemographic factorsPlus clinical factorsPlus prior utilization
Readmission and groupN%aHR95% CIaHR95% CIaHR95% CI
Readmission between 31 and 210 days postdischarge        
 No visit (reference)1,69826      
 PCP only90122.87.80–.94.83.77–.90.88.81–.96
 Psychiatrist only1,16222.81.75–.87.80.74–.86.84.77–.90
 Both PCP and psychiatrist66021.82.75–.89.77.71–.85.83.75–.91
Readmission or death between 31 and 210 days postdischarge        
 No visit (reference)1,74326      
 PCP only93423.87.81–.95.84.77–.91.88.82–.96
 Psychiatrist only1,18022.80.75–.87.79.74–.86.83.77–.90
 Both PCP and psychiatrist67522.81.74–.89.77.70–.85.82.75–.90
Readmission between 31 and 210 days postdischarge by timing of postdischarge physician visit        
 No visit (reference)1,69826      
 Between 1 and 7 days1,11822    .86.80–.93
 Between 8 and 14 days76121    .82.75–.90
 Between 15 and 30 days84422    .85.78–.93
a
aHR, adjusted hazard ratio. Estimates were adjusted for demographic factors (age, sex, neighborhood income, and rural versus urban residence), clinical factors (Johns Hopkins Aggregated Diagnostic Groups in the preceding 12 months and the following rating scales included in the Inter-Resident Assessment Instrument for Mental Health (19,20): Aggressive Behavior Scale, Activities of Daily Living Scale, Cognitive Performance Scale, Depression Rating Scale, Positive and Negative Syndrome Scale, CAGE Questionnaire, Suicide Behaviors Scale, and Global Assessment of Functioning Scale), and prior health service utilization (total number of psychiatric hospitalizations and emergency department visits in the preceding 12 months). Models included the following variables sequentially: demographic variables only, then demographic plus clinical factors, then demographic plus clinical factors plus prior health service utilization variables, except for readmission by timing of postdischarge visit.
In stratified analyses, 66% of patients were in the highest psychiatric readmission risk tertile, 26% were in the medium tertile, and 8% were in the low tertile [see online supplement]. Psychiatric readmission rates for the low, middle, and high tertiles were 15%, 18%, and 26%, respectively. For patients in the low tertile, postdischarge follow-up was not associated with a significant reduction in psychiatric readmission rates (Figure 1, panel A). For patients in the medium tertile, only those seen by a psychiatrist had a significant reduction in psychiatric readmission rates (aHR=.82, 95% confidence interval [CI]=.69–.97) (Figure 1, panel B). However, for patients in the high-risk tertile, each of the follow-up groups was associated with a significantly lower risk of psychiatric readmission, compared with the no-visit patients in the high-risk tertile group, whose readmission rate was 29%. Follow-up by a PCP or a psychiatrist was associated with a reduction in readmission rates of about 15%, compared with the no-follow-up group (PCP only, aHR=.85, CI=.77–.94; psychiatrist only, aHR=.84, CI=.77–.92). Seeing both a psychiatrist and a PCP was associated with a 19% reduction in psychiatric readmission rates, compared with the no-follow-up group (aHR=.81, CI=.73–.90) (Figure 1, panel C).
FIGURE 1. Readmission-free days after hospital discharge among patients with schizophrenia, by readmission risk tertile and whether they had a follow-up visit with a primary care physician (PCP) or a psychiatrist
Psychiatric readmission rates were reduced by a similar magnitude, compared with the no-visit group, when the first follow-up visit with any physician was categorized on the basis of timing, as shown in the model that included all covariates (Table 2): a visit to any physician within one to seven days postdischarge, aHR =.86; within eight to 14 days, aHR=.82; within 15 to 30 days, aHR=.85.
The proportions of patients in each physician follow-up category who saw either a PCP or a psychiatrist between 31 and 60 days and between 31 and 210 days are shown in Table 3. The patterns observed in the first 30 days postdischarge were similar to the patterns seen between 31 and 210 days,
TABLE 3. Physician follow-up visits after 31 days postdischarge among patients with schizophrenia, by whether they had a visit with a primary care physician (PCP) or a psychiatrist within 30 days of discharge
 No physician follow-up (N=6,706)PCP only (N=4,058)Psychiatrist only (N=5,383)PCP and psychiatrist (N=3,097)
Timing and type of visitN%N%N%N%
Visit between 31 and 60 days postdischarge        
 Any PCP visit1,263192,348581,038191,66054
 Any psychiatrist visit1,35920850213,611272,02966
Visit between 31 and 210 days postdischarge        
 Any PCP visit3,392513,609902,954552,68087
 Any psychiatrist visit2,947441,897474,967922,82292

Discussion

For patients with schizophrenia, seeing a PCP or a psychiatrist within 30 days after a psychiatric hospitalization was associated with a significant but modest reduction in the likelihood of a psychiatric readmission within 31 to 210 days. This result was driven primarily by the two-thirds of patients at high risk of psychiatric readmission at discharge. Compared with patients in the high-risk group who had no follow-up visit with a physician, patients who were followed up by a PCP or psychiatrist were between 15% and 19% less likely to be readmitted. In the overall sample, more than one-third of patients did not see a physician within 30 days of discharge, even though half had seen a PCP and two in five had seen a psychiatrist in the six months preceding the index admission. To our knowledge, this is one of the first studies to evaluate the association between one mental health performance indicator—postdischarge follow-up by a physician—and another universally measured performance indicator—psychiatric readmission.
Few studies have evaluated the impact of physician follow-up on postdischarge transition to the community (5). In a large U.S. Medicaid study of postdischarge access to care among individuals with schizophrenia, 41% of patients received no outpatient care in the 30 days postdischarge (24), slightly higher than the rate in our study. However, the Medicaid study did not evaluate the impact of postdischarge access to care on readmission rates. One study assessed the impact of postdischarge access to care, but it focused on patients with comorbid substance use and psychiatric disorders and found that postdischarge addiction care, and not psychiatric care, reduced readmissions (25). A recent study evaluated postdischarge follow-up by a mental health professional or by a primary care provider among patients discharged with a diagnosis of depression or schizophrenia and included psychiatric readmission as an outcome (6). Postdischarge follow-up did not reduce readmission rates in that study, but the study had limited generalizability because it included only Medicaid recipients and employed a complex intervention to integrate and coordinate care for individuals with complex chronic conditions. Thus, to our knowledge, our study is one of the first to systematically evaluate the impact of postdischarge physician follow-up among patients with schizophrenia.
Although seeing any physician was associated with a modest reduction in the readmission rate for the entire cohort, the most striking finding was the impact for patients at high risk of readmission. By 210 days, more than one in four of those at highest risk experienced a psychiatric readmission, and physician follow-up reduced the risk of readmission by up to 19%. The fact that patients at high risk of readmission benefited from postdischarge physician follow-up is consistent with evidence that interventions to help with the transition from the hospital to community-based settings are most effective among patients with high readmission risk (5). By contrast, postdischarge physician follow-up had no impact on readmission rates in the lowest risk category. However, postdischarge follow-up is associated with a number of processes of care, such as adherence to the pharmacological treatment, that helped stabilize the individual during hospitalization and engagement with other services that support postdischarge stabilization. The patients at low and medium risk of readmission may have benefited from physician follow-up in ways not captured by our primary outcome of readmission.
Our study had some strengths and limitations. It was a population-based study that captured all hospitalizations and postdischarge readmissions associated with a diagnosis of schizophrenia in Ontario during the study period. We had access to a wide array of sociodemographic and clinical variables that allowed us to more comprehensively control for clinical severity than is typical for studies using administrative databases. However, we cannot exclude the possibility of unmeasured confounding; for example, family support, which we were unable to measure, may be associated with both a higher likelihood of physician follow-up and a reduced likelihood of readmission. Also, we did not have information about nonphysician postdischarge care in the community, which could have affected readmission rates. However, follow-up care only by nonphysicians is uncommon in Ontario, whereas there is anecdotal evidence that follow-up care with physicians only is common, particularly in rural areas with fewer community-based resources than urban centers. Finally, this was an observational study and thus we cannot assume that postdischarge follow-up was a causal factor affecting readmission; individuals who received postdischarge follow-up may also have been less likely to be readmitted, and there are factors that may affect readmission (such as access to non–physician-based services postdischarge) that we were not able to measure and that may have confounded the findings. However, if such selection bias existed, it was not observed equally across all readmission risk categories, and it seems unlikely that it would be a factor only among individuals with high readmission risk. Finally, we did not measure the quantity and timing of outpatient visits; these factors should be a focus of future research.

Conclusions

A substantial proportion of patients with schizophrenia did not see any physician within 30 days of discharge, and they experienced a high rate of readmission postdischarge. Seeing a physician was associated with a modest reduction in readmission risk. Results indicate that physician follow-up is mostly likely to have an impact on the majority of patients at high risk of readmission. Postdischarge physician follow-up is a quality indicator, and our study provides evidence that physician follow-up has the greatest impact among patients at high risk of readmission and, therefore, with the greatest need for follow-up. Other factors that contribute to the high readmission rate of patients with schizophrenia need to be better understood in order to design interventions that improve their postdischarge outcomes.

Footnote

The study results and conclusions are those of the authors, and should not be attributed to any of the funding agencies or sponsoring agencies. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.

Supplementary Material

File (appi.ps.201600507.ds001.pdf)

References

1.
Hospital Mental Health Services in Canada, 2009–2010. Ottawa, Canadian Institute for Health Information, 2012
2.
Olfson M, Mechanic D, Boyer CA, et al: Assessing clinical predictions of early rehospitalization in schizophrenia. Journal of Nervous and Mental Disease 187:721–729, 1999
3.
Marshall M, Lockwood A: Assertive community treatment for people with severe mental disorders. Cochrane Database of Systematic Reviews (2):CD001089, 2000
4.
Quinlivan R, Hough R, Crowell A, et al: Service utilization and costs of care for severely mentally ill clients in an intensive case management program. Psychiatric Services 46:365–371, 1995
5.
Vigod SN, Kurdyak PA, Dennis CL, et al: Transitional interventions to reduce early psychiatric readmissions in adults: systematic review. British Journal of Psychiatry 202:187–194, 2013
6.
Beadles CA, Ellis AR, Lichstein JC, et al: First outpatient follow-up after psychiatric hospitalization: does one size fit all? Psychiatric Services 66:364–372, 2015
7.
Goldner EM, Jones W, Fang ML: Access to and waiting time for psychiatrist services in a Canadian urban area: a study in real time. Canadian Journal of Psychiatry 56:474–480, 2011
8.
Kurdyak P, Stukel TA, Goldbloom D, et al: Universal coverage without universal access: a study of psychiatrist supply and practice patterns in Ontario. Open Medicine 8:e87–e99, 2014
9.
Malowney M, Keltz S, Fischer D, et al: Availability of outpatient care from psychiatrists: a simulated-patient study in three US cities. Psychiatric Services 66:94–96, 2015
10.
Oud MJ, Meyboom-de Jong B: Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Family Practice 10:32, 2009
11.
Dombrovski A, Rosenstock J: Bridging general medicine and psychiatry: providing general medical and preventive care for the severely mentally ill. Current Opinion in Psychiatry 17:7, 2004
12.
Druss BG, Bornemann TH: Improving health and health care for persons with serious mental illness: the window for US federal policy change. JAMA 303:1972–1973, 2010
13.
Gilbody S, Bower P, Fletcher J, et al: Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Archives of Internal Medicine 166:2314–2321, 2006
14.
Katon WJ, Lin EH, Von Korff M, et al: Collaborative care for patients with depression and chronic illnesses. New England Journal of Medicine 363:2611–2620, 2010
15.
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. Leicester, United Kingdom, National Collaborating Centre for Mental Health, 2009
16.
Steele LS, Glazier RH, Lin E, et al: Using administrative data to measure ambulatory mental health service provision in primary care. Medical Care 42:960–965, 2004
17.
Austin PC, van Walraven C, Wodchis WP, et al: Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada. Medical Care 49:932–939, 2011
18.
Austin PC, Newman A, Kurdyak PA: Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a population-based cohort of adults with schizophrenia in Ontario, Canada. Psychiatry Research 196:32–37, 2012
19.
Martin L, Hirdes JP: Mental health needs and service use in Ontario. Healthcare Management Forum 22:40–46, 2009
20.
Perlman CM, Hirdes JP, Barbaree H, et al: Development of mental health quality indicators (MHQIs) for inpatient psychiatry based on the interRAI Mental Health Assessment. BMC Health Services Research 13:15, 2013
21.
Diagnostic and Statistical Manual of Mental Disorders: Text Revision. Washington, DC, American Psychiatric Association, 2000
22.
Vigod SN, Kurdyak PA, Seitz D, et al: READMIT: a clinical risk index to predict 30-day readmission after discharge from acute psychiatric units. Journal of Psychiatric Research 61:205–213, 2015
23.
SAS, Version 9: Installation and Administration Information. Cary, NC, SAS Institute, 2007
24.
Olfson M, Marcus SC, Doshi JA: Continuity of care after inpatient discharge of patients with schizophrenia in the Medicaid program: a retrospective longitudinal cohort analysis. Journal of Clinical Psychiatry 71:831–838, 2010
25.
Ilgen MA, Hu KU, Moos RH, et al: Continuing care after inpatient psychiatric treatment for patients with psychiatric and substance use disorders. Psychiatric Services 59:982–988, 2008

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services

Cover: Understanding, by Michael Olszewski, 1984. Dyed and pleated silk plain weave with silk embroidery. Philadelphia Museum of Art, gift of Nancy and David Bergman, 2015.

Psychiatric Services
Pages: 61 - 68
PubMed: 28859584

History

Received: 2 November 2016
Revision received: 20 April 2017
Revision received: 3 June 2017
Accepted: 16 June 2017
Published online: 1 September 2017
Published in print: January 01, 2018

Keywords

  1. Schizophrenia
  2. Service delivery systems
  3. Outcome studies

Authors

Details

Paul Kurdyak, M.D., Ph.D. [email protected]
Dr. Kurdyak is with the Centre for Addiction and Mental Health and the Institute for Clinical Evaluation, Toronto. Dr. Vigod is with the Department of Psychiatry, Women’s College Hospital, Toronto. She is also with the Department of Psychiatry, University of Toronto, where Dr. Mulsant is affiliated. Ms. Newman, Mr. Giannakeas, and Dr. Stukel are with the Institute for Clinical Evaluative Sciences, Toronto.
Simone Natalie Vigod, M.D., M.Sc.
Dr. Kurdyak is with the Centre for Addiction and Mental Health and the Institute for Clinical Evaluation, Toronto. Dr. Vigod is with the Department of Psychiatry, Women’s College Hospital, Toronto. She is also with the Department of Psychiatry, University of Toronto, where Dr. Mulsant is affiliated. Ms. Newman, Mr. Giannakeas, and Dr. Stukel are with the Institute for Clinical Evaluative Sciences, Toronto.
Alice Newman, M.Sc.
Dr. Kurdyak is with the Centre for Addiction and Mental Health and the Institute for Clinical Evaluation, Toronto. Dr. Vigod is with the Department of Psychiatry, Women’s College Hospital, Toronto. She is also with the Department of Psychiatry, University of Toronto, where Dr. Mulsant is affiliated. Ms. Newman, Mr. Giannakeas, and Dr. Stukel are with the Institute for Clinical Evaluative Sciences, Toronto.
Vasily Giannakeas, M.P.H.
Dr. Kurdyak is with the Centre for Addiction and Mental Health and the Institute for Clinical Evaluation, Toronto. Dr. Vigod is with the Department of Psychiatry, Women’s College Hospital, Toronto. She is also with the Department of Psychiatry, University of Toronto, where Dr. Mulsant is affiliated. Ms. Newman, Mr. Giannakeas, and Dr. Stukel are with the Institute for Clinical Evaluative Sciences, Toronto.
Benoit H. Mulsant, M.D., M.S.
Dr. Kurdyak is with the Centre for Addiction and Mental Health and the Institute for Clinical Evaluation, Toronto. Dr. Vigod is with the Department of Psychiatry, Women’s College Hospital, Toronto. She is also with the Department of Psychiatry, University of Toronto, where Dr. Mulsant is affiliated. Ms. Newman, Mr. Giannakeas, and Dr. Stukel are with the Institute for Clinical Evaluative Sciences, Toronto.
Therese Stukel, Ph.D.
Dr. Kurdyak is with the Centre for Addiction and Mental Health and the Institute for Clinical Evaluation, Toronto. Dr. Vigod is with the Department of Psychiatry, Women’s College Hospital, Toronto. She is also with the Department of Psychiatry, University of Toronto, where Dr. Mulsant is affiliated. Ms. Newman, Mr. Giannakeas, and Dr. Stukel are with the Institute for Clinical Evaluative Sciences, Toronto.

Notes

Send correspondence to Dr. Kurdyak (e-mail: [email protected]).

Competing Interests

Dr. Mulsant reports receipt of research support from Capital Solution Design, Eli Lilly, HAPPYneuron, and Pfizer and ownership of stock in General Electric. The other authors report no financial relationships with commercial interests.

Funding Information

Ontario Ministry of Health and Long-Term Care10.13039/501100000226: Health Systems Research Fund Capacity Award #06682
This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Dr. Kurdyak received an operating grant (grant 06682) from the Ontario MOHLTC Research Fund Capacity Award to fund this study.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Psychiatric Services

PPV Articles - Psychiatric Services

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share